Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Thoracic 3Head & Neck 3Gynecologic 3Gastrointestinal 3Dermatologic 3Breast 3Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 57Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Myelomonocytic, Chronic 15Myeloproliferative Disorders 12Lymphoma 12Leukemia, Biphenotypic, Acute 11Burkitt Lymphoma 11Lymphoma, Follicular 9Leukemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 8Hematologic Neoplasms 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell, Marginal Zone 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Leukemia, Monocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Lymphoma, T-Cell, Cutaneous 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Congenital Abnormalities 4Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Acute 3Leukemia, Hairy Cell 3

Interventions

pertuzumab 2aflibercept 2Trastuzumab 2Polymerase Chain Reaction 2Nicotine 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Counseling 2Bupropion 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1cc-486 1capivasertib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Biopsy × Other hematologic neoplasm × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡